Premarket Mover: Lineage Cell Therapeutics Inc (LCTX) Down 2.14%

Lineage Cell Therapeutics Inc (LCTX) has fallen Thursday morning, with the stock decreasing -2.14% in pre-market trading to 1.37. LCTX's short-term technical score of 59 indicates that the stock has traded more bullishly over the last month than 59% of stocks on the market. In the Biotechnology industry, which ranks 104 out of 146 industries, LCTX ranks higher than 71% of stocks. Lineage Cell Therapeutics Inc has risen 34.62% over the past month, closing at $1.04 on February 29. During this period of time, the stock fell as low as $1.04 and as high as $1.45. LCTX has an average analyst recommendation of Strong Buy. The company has an average price target of $4.67.

LCTX has an Overall Score of 68. Find out what this means to you and get the rest of the rankings on LCTX!

See Full LCTX Report

Lineage Cell Therapeutics Inc has a Long-Term Technical rank of 56. This means that trading over the last 200 trading days has placed the company in the upper half of stocks with 44% of the market scoring higher. In the Biotechnology industry which is number 69 by this metric, LCTX ranks better than 69% of stocks.

Important Dates for Investors in LCTX:

-Lineage Cell Therapeutics Inc is set to release earnings on 2024-05-09. Over the last 12 months, the company has reported EPS of $-0.12. -We do not have a set dividend date for Lineage Cell Therapeutics Inc at this time. Click Here To Get The Full Report on Lineage Cell Therapeutics Inc (LCTX)